TP53 mutations or 17p abnormalities are frequently observed in t‐MNs and associated with complex karyotype, a reduced probability of achieving response after induction chemotherapy and a poor outcome, as shown by Lindsley et al.48Nowadays, prognosis of TP53 mutated t‐AML, according to new AML classifications26 must consider variant allelic frequency, single or multihit characteristic and presence of comutations.49 This evidence concerns the gene TP53 and acute myeloid leukemia.